SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 5c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.31), $0.05 better than the analyst estimate of ($0.36).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating